• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Vericel Corporation

    3/19/26 7:31:10 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VCEL alert in real time by email
    DEFA14A 1 lvcel2026_defa14a.htm DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS VERICEL CORPORATION - DEFA 14A

    UNITED STATES

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, DC 20549

     

    SCHEDULE 14A

     

    PROXY STATEMENT PURSUANT TO SECTION 14(a)
    OF THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.     )

     

      Filed by the Registrant   Filed by a Party other than the Registrant

     

    Check the appropriate box:
    Preliminary Proxy Statement
    Confidential, for Use of the Commission Only (as permitted by Rule 14A-6(E)(2))
    Definitive Proxy Statement
    Definitive Additional Materials
    Soliciting Material under §240.14a-12

     

    VERICEL CORPORATION

     

     

    (Name of Registrant as Specified in Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):
    No fee required.
    Fee paid previously with preliminary materials.
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
     

     

          Your Vote Counts!  
                                     VERICEL CORPORATION  
          2026 Annual Meeting of Shareholders  
          Vote by April 28, 2026  
       

     



    VERICEL CORPORATION
    ATTN: SEAN C. FLYNN
    64 SIDNEY STREET
    CAMBRIDGE, MA 02139

      11:59 PM ET  
           
           
             
             
             
             
             
             
               V83886-P45794      

     

    You invested in VERICEL CORPORATION and it’s time to vote!

    You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the Annual Meeting of Shareholders to be held on April 29, 2026 at 9:00 a.m. ET.

     

    Get informed before you vote

    View the 2026 Notice of Virtual Annual Meeting of Shareholders and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the voting materials by requesting prior to April 15, 2026. If you would like to request a copy of the voting materials, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

     

         
    For complete information and to vote, visit www.ProxyVote.com
    Control #
         

     

    Smartphone users

     

    Point your camera here and
    vote without entering a
    control number

       

    Vote Virtually at the Meeting*

     

    April 29, 2026
    9:00 a.m. ET


     

     

    Virtually at:
    www.virtualshareholdermeeting.com/VCEL2026

     

    Vote by Mail

    You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

           

     

    *Vericel will be hosting the Annual Meeting live via the Internet. You will not be able to attend the Annual Meeting in person. You can listen to and participate in the Annual Meeting live via the Internet at www.virtualshareholdermeeting.com/VCEL2026. The Annual Meeting webcast will begin promptly at 9:00 a.m. ET on April 29, 2026. We encourage you to access the Annual Meeting webcast prior to the start time. You will need the 16-digit control number listed above to be able to vote these shares during the Annual Meeting. Instructions on how to connect to the Annual Meeting and participate via the Internet, including how to demonstrate proof of stock ownership, will be posted at www.virtualshareholdermeeting.com/VCEL2026 two weeks prior to the date of the Annual Meeting.

     
    Vote at www.ProxyVote.com  

     

    THIS IS NOT A VOTABLE BALLOT

     

    This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

       

     

    Voting Items Board
    Recommends
    1. Election of Directors  
      Nominees:              
     

    01)  Robert L. Zerbe

    02)  Alan L. Rubino

    03)  Heidi Hagen

    04)  Kevin F. McLaughlin

             

    05)  Paul K. Wotton

    06)  Dominick C. Colangelo

    07)  Lisa Wright

     

    For
    2. To approve, on an advisory basis, the compensation of Vericel Corporation’s named executive officers. For
    3. To ratify the appointment of PricewaterhouseCoopers LLP as Vericel Corporation’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For
    NOTE: In their discretion, the proxies are authorized to vote upon any other matters that are properly brought by or at the direction of the Board of Directors before the Annual Meeting and at any adjournments or postponements thereof. Even if you are planning to attend the meeting virtually, you are urged to sign and mail this Proxy in the return envelope so that the stock may be represented at the meeting.
       
       
    Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.
     
    V83887-P45794
     
    Get the next $VCEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VCEL

    DatePrice TargetRatingAnalyst
    9/17/2025Buy → Neutral
    BTIG Research
    8/9/2024$57.00Buy
    Canaccord Genuity
    6/20/2024$55.00Buy
    TD Cowen
    1/25/2024$39.00 → $51.00Hold → Buy
    Truist
    8/8/2023$39.00Neutral → Buy
    BTIG Research
    11/10/2022Buy → Neutral
    BTIG Research
    11/9/2022Buy → Hold
    Truist
    10/14/2022$40.00Overweight
    Stephens
    More analyst ratings

    $VCEL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Vericel Corporation

    SCHEDULE 13G/A - Vericel Corp (0000887359) (Subject)

    3/27/26 1:55:51 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Vericel Corporation

    144 - Vericel Corp (0000887359) (Subject)

    3/23/26 4:08:21 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Vericel Corporation

    DEF 14A - Vericel Corp (0000887359) (Filer)

    3/19/26 7:30:37 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Hopper Jonathan Mark

    4 - Vericel Corp (0000887359) (Issuer)

    4/6/26 4:05:42 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Rubino Alan L

    4 - Vericel Corp (0000887359) (Issuer)

    3/27/26 4:05:34 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Hagen Heidi

    4 - Vericel Corp (0000887359) (Issuer)

    3/25/26 4:05:12 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vericel downgraded by BTIG Research

    BTIG Research downgraded Vericel from Buy to Neutral

    9/17/25 7:57:35 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Canaccord Genuity initiated coverage on Vericel with a new price target

    Canaccord Genuity initiated coverage of Vericel with a rating of Buy and set a new price target of $57.00

    8/9/24 8:07:19 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TD Cowen initiated coverage on Vericel with a new price target

    TD Cowen initiated coverage of Vericel with a rating of Buy and set a new price target of $55.00

    6/20/24 7:39:49 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines

    Issued on behalf of Avaí Bio, Inc.USANewsGroup.com News CommentaryVANCOUVER, BC, April 6, 2026 /CNW/ -- The global cell therapy manufacturing market is on track to nearly double, from $7.17 billion in 2026 to over $14 billion by 2035[1]. The science has been proving itself for years. What most of these companies still lack is the production backbone to actually deliver at scale: GMP qualified facilities, traceable cell banks, and manufacturing processes that regulators will sign off on. The FDA accelerated the timeline in early 2026 by formalizing flexible manufacturing and quality control oversight for cell and gene therapies, clearing a path that had stalled the jump from clinical validati

    4/6/26 1:10:00 PM ET
    $ELDN
    $SANA
    $VCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

    MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, today announced that Vericel Corporation (NASDAQ:VCEL), its exclusive distributor of NexoBrid® in North America, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Vericel reported that the contract is for the procureme

    4/2/26 3:26:11 PM ET
    $MDWD
    $VCEL
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid

    CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the procurement of NexoBrid®, establishment and maintenance of a Vendor Managed Inventory (VMI) system, design and validation of a U.S based manufacturing facility, and the development of a next generation formulation and additional indicatio

    4/2/26 2:40:00 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Vericel Corporation

    SC 13G/A - Vericel Corp (0000887359) (Subject)

    11/14/24 1:46:57 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vericel Corporation

    SC 13G/A - Vericel Corp (0000887359) (Subject)

    11/14/24 6:19:59 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vericel Corporation

    SC 13G/A - Vericel Corp (0000887359) (Subject)

    10/18/24 12:21:30 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Financials

    Live finance-specific insights

    View All

    Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results

    Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross Margin of 79% and Adjusted EBITDA Margin of 40% Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Total net revenue growth of 23% to $92.9 millionMACI® net

    2/26/26 7:55:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026

    CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the web

    2/12/26 8:30:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vericel Reports Third Quarter 2025 Financial Results

    Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25% Record Third Quarter Operating Cash Flow of $22.1 Million More than 800 MACI Arthro Surgeons Trained to Date Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Total net revenue of $67.5 millionMACI® net revenue growth o

    11/6/25 7:55:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $VCEL
    Leadership Updates

    Live Leadership Updates

    View All

    Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer

    CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel's Head of Human Resources since September 2010. Ms. Mahoney joins Vericel with more than 20 years of experience across the life sciences and medical device sectors, most recently serving as Chief Human Resources Officer at Abiomed, a global medical device company that was acquired by Johnson & Johnson in December 2022. At Abiomed, Ms. Mahoney led all aspects of HR strategy and

    7/22/24 8:30:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    A-Alpha Bio Welcomes Heidi Hagen to Its Board of Directors

    Hagen, Former Chief Technical Officer of Sonoma Biotherapeutics, Joins as A-Alpha's First Independent Board Member SEATTLE, June 27, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors. Hagen will be A-Alpha Bio's first independent board member. Hagen has been a leader in the Biotechnology industry for 30 years. Over the course of her career, she has built an extensive track record in leading strategy and operations to progress innovative technologies from ideation to commercialization. Having been a core member of pharma companie

    6/27/23 9:00:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of Directors

    New Independent Board Chair, Dr. Paul K. Wotton, brings 35 years of experience building private and public biopharmaceutical companies with significant business development expertise. Kytopen, an MIT-spin out and biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms, today announced the appointment of Paul K. Wotton, Ph.D. to Chair the Kytopen Board of Directors. Following the appointment of Dr. Wotton, the Board will comprise of five directors including Ann DeWitt, Adam Wieschhaus, Cullen Buie, and Paulo Garcia. Dr. Paul Wotton received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham and is an experienced CEO,

    1/5/23 9:00:00 AM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care